Small delays in cancer treatment can up death risk by 10%, finds study

Delaying cancer treatment by just for even one month can increase the risk of death by up to 10%, say researchers, adding that minimising delays to treatment could improve cancer survival rates

Chip-based cancer test may replace painful bone biopsy
IANS Toronto
2 min read Last Updated : Nov 05 2020 | 4:56 PM IST

Delaying cancer treatment by just for even one month can increase the risk of death by up to 10 per cent, say researchers, adding that minimising delays to treatment could improve cancer survival rates.

The study, published in the journal 'The BMJ', found that there was a significant impact on a person's mortality if their treatment was delayed, whether that be surgical, systemic therapy (such as chemotherapy), or radiotherapy for seven types of cancer.

Globally, health systems have problems with cancer treatment delays and it is already widely accepted that such delays can have adverse consequences on a patient's outcome.

But the precise impact of delays from diagnosis to receipt of treatment on mortality has not been thoroughly analysed.

Therefore, a team of researchers from Queen's University in Canada carried out a review and analysis of relevant studies into the subject published between January 2000 and April 2020.

These studies had data on surgical interventions, systemic therapy (such as chemotherapy), or radiotherapy for seven forms of cancer - bladder, breast, colon, rectum, lung, cervix, and head and neck - that together, represent 44 per cent of all incident cancers globally.

Their main outcome measure was the risk to overall survival per four-week delay for each indication and delays were measured from diagnosis to first treatment, or from the completion of one treatment to the start of the next.

They found 34 suitable studies for 17 types of conditions that needed to be treated (indications) involving more than 1.2 million patients, collectively.

The association between delay and increased mortality was significant for 13 of these 17 indications.

"Analysis of the results showed that across all three treatment approaches, a treatment delay of four weeks was associated with an increase in the risk of death," the study authors wrote.

For surgery, this was a 6-8 per cent increase in the risk of death for every four-week treatment delay whereas the impact was even more marked for some radiotherapy systemic treatments.

In addition, the researchers calculated that delays of up to eight weeks and 12 weeks and found further increased in the risk of death.

"A four-week delay in treatment is associated with an increase in mortality across all common forms of cancer treatment, with longer delays being increasingly detrimental," the study authors noted.

--IANS

bu/sdr/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :cancer

First Published: Nov 05 2020 | 4:54 PM IST

Next Story